Combined antiviral treatment by pegilated interferon α-2а and ribavirin at chronic hepatitis C in patients taking moderate doses of alcohol
Abstract
Aim of investigation. Effect of moderate doses of alcohol (21–39 g of ethanol/day) on the course of chronic hepatitis C (CH C) and results of antiviral therapy by pegilated interferon-alpha-2а (PEG-IFN-α-2а) in combination to ribavirin were estimated.
Stuff and methods. Forty seven patients with chronic hepatitis C that have been distributed in 2 groups were included to original study. The group 1 has consisted of 21 patients, suffering of CH C with the alcohol burden in past history. This group included 15 men and 6 women in the age from 19 to 52 years (average 33,3±10,8), of them 12 had genotype 1 HCV, 9 – genotype 3. Group 2 included 26 patients who did not take alcohol or did it incidentally in small doses. Of them 18 were men and 8 — women in the age of 19 to 58 years (average 36,5±11,04), of them 17 had genotype 1 HCV and 9 – genotype 3. The dose of alcohol in milliliters per day was recalculated to grams by Widmark formula. All patients underwent needle liver biopsy with evaluation of histological activity index (HAI) and index of fibrosis (IF).
Results. In CH C patients, taking medium doses of alcohol (21–39 g of ethanol/day), activity of serum transaminases and g-glutamyltransferase (GGT) was significantly higher, than in patients that either did not take alcohol, or drink incidentally in small doses. However, there were no statistically significant differences between groups by HAI and IF. No significant difference was revealed on efficiency and tolerability of therapy as well. Frequency of late relapses after combined antiviral treatment PEG-IFN-α-2а/ribavirin was 5% and it does not depend on alcoholic abuse in past history of patient. Only two factors had effect on the rate of sustained virologic response (SVR) – virus genotype and presence of early virologic response (EVR).
Conclusion. Results of the original investigation give no testimony for complete abandoning of alcohol use by patients with chronic hepatitis C and not having alcohol or narcotic addiction.
About the Authors
Sh. A. OndosRussian Federation
M. V. Mayevskaya
Russian Federation
Ch. S. Pavlov
Russian Federation
V. T. Ivaskin
Russian Federation
References
1. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В.Т. Ивашкина – 2-е изд., испр. и доп. – М.: Изд. дом «М-Вести», 2005. – 536 с.
2. Маевская М.В. Клинические особенности алкогольно-вирусных поражений печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2004. – Т. 14, № 2. – С. 17–21.
3. Маевская М.В., Шарафеева О.П., Ведерникова А.В., Ивашкин В.Т. Влияние вирусов гепатита на продолжительность жизни больных алкогольным циррозом печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2004. – Т. 14, № 2. – С. 22–28.
4. Маевская М.В. Хронические диффузные заболевания печени, вызванные алкоголем и вирусами гепатитов В и С – Дис. ... д-ра мед. наук. – М., 2006. – 200 с.
5. Махов В.М. Алкогольная болезнь печени и поджелудочной железы // Практикующий врач. – 2004. – № 1. – С. 30–35.
6. Bellentani S., Pozzato G., Saccoccio G. et al. Clinical course and risk factors for hepatitis C virus related liver disease in the general population: report from the Dyonisos study // Gut. – 1999. – Vol. 44. – P. 847–880.
7. Bruno S., Battezzati P.M., Belati G. et al. Lond-tern beneticial effects in sustained responders to interferon-alpha therapy of chronic hepatitis C // J. Hepatol. – 2001. – Vol. 34. – P. 748–755.
8. Castillo I., Rodriguez-Inigo E., Lopez-Alcorocho J.M. et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment // Clin. Infect. Dis. – 2006. – Vol. 43, N 10. – P. 1277–1283.
9. Hosogaya S., Ozaki Y., Enomoto N., Akahane Y. Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C // Transl. Res. – 2006. – Vol. 148, N 2. – P. 79–86.
10. Kuntz E., Kuntz H.D. Hepatology principles and practice. – Berlin, Heiderberg: Springer-Verlag, 2002. – P. 52–54.
11. Monzoni A., Masutti F., Saccoccio G. et al. Genetic determinants of ethanol-induced liver damage // Mol. Med. – 2001. – Vol. 7, N 4. – P. 255–262.
12. National Institutes of Health Consensus Development Conference Management of Hepatitis C: 2002 // Hepatology. – 2002. – Vol. 36 (suppl. 1). – P. 220–225.
13. Peters M.G., Terrault N.A. Alcohol use and hepatitis C // Hepatology. – 2002. – Vol. 36, N 5. – P. 220–225.
14. Snoeck E., Wade J.F., Duff F., Lamb M. Predicting sustained virological response and anemia in chronic hepatitis C patients treated with peginterferon alfa-2a(40KD) plus ribavirin // Br. J. Clin. Pharmacol. – 2006. – Vol. 62, N 6. – P. 699–709.
15. Teon N.C., Farrell G.C. Management of chronic hepatitis C virus infection: a new era of disease control // J. Intern. Med. – 2004. – Vol. 34. – P. 324–337.
16. Veldt B.J., Saracco G., Boyer N. et al. Long-term clinical outcomes of chronic hepatitis C patients with sustained virological response to interferon monotherapy // Gut. – 2004. – Vol. 53. – P. 1504–1508.
17. Xie Y., Xu D.Z., Lu Z.M., Luo K.X. Predictive factors for sustained response ti interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial // Hepatobiliary Pancreat. Dis. Int. – 2005. – Vol. 4, N 2. – P. 213–219.
Review
For citations:
Ondos Sh.A., Mayevskaya M.V., Pavlov Ch.S., Ivaskin V.T. Combined antiviral treatment by pegilated interferon α-2а and ribavirin at chronic hepatitis C in patients taking moderate doses of alcohol. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008;18(2):35-41. (In Russ.)
Views:
3
Email this article 
